Principal Scientist/Associate Director, Process Chemistry

Who We Are

: Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions.

Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. com or follow us on X (formerly Twitter) or LinkedIn . How we work: PIONEER : We are courageous, resilient and rigorous in our mission to improve patients’ lives through our revolutionary degrader medicines.

COLLABORATE : We value trust + transparency from everyone. Our goals are shared, our decisions data-driven and our camaraderie genuine. BELONG : We recognize our differences, inviting curiosity and inclusivity, so that our people are valued, seen, and heard.

How you’ll make an impact: As an Associate Director of Drug Substance Development, you will serve as the accountable Drug Substance lead for one or more development programs, owning DS strategy, execution, and delivery from late discovery through clinical development. Use scientific, data-drive, and risk-based approaches to clinical and commercial route and process innovation and development, guided by safety and green chemistry principles. Provide technical leadership and decision‑making oversight for outsourced Drug Substance development activities at CROs and CDMOs, ensuring quality, timelines, and scientific rigor.

Serve as the Drug Substance technology lead for internal and external knowledge transfers, including authoring transfer strategies, defining success criteria, and supporting manufacturing execution. Collaborate with Drug Product and Analytical colleagues to ensure the Drug Substance physical attributes are understood, controlled, and are appropriate for Drug Product manufacturing. Ensure stage appropriate data is generated and documented; serve as contributing author and technical reviewer of Drug Substance sections of regulatory filings.

Collaborate effectively with internal and external stakeholders to deliver on program objectives. D. S.

in Chemistry or Chemical Engineering with at least 12 years’ experience in Drug Substance Development. Experience with: Bringing small molecule assets from late discovery through mid-phase clinical trials. Serving as the Drug Substance lead on fully integrated Chemistry, Manufacturing, and Control (CMC) teams.

Directing CRO and CDMO partners. Writing and reviewing Drug Substance related technical documents. Deep understanding of small molecule drug development; understand how CMC disciplines integrate and partner with associated functional areas such as Quality, Non-clinical Safety, Clinical, Regulatory, and Intellectual Property Protection.

Requirements

, regulatory guidelines and expectations. Willingness and ability to work hands-on and with a sense of urgency in a fast-paced, agile environment. Demonstrated ability to make sound, risk‑based scientific and business decisions in ambiguous, fast‑paced development environments.

Ability to conduct, manage, and communicate risk assessments. Preferable Experience: Ability to develop data driven crystallization processes based on an understanding and application of fundamental principles.